Eight studies presenting two NOAC classes were selected: DTI: RE-LY [23] and RE-DUAL PCI [4]: dabigatran 150 mg n = 6839, dabigatran 110 mg n = 6996 (total 13,835), and FXa inhibitors: ROCKET rivaroxaban 20 mg [24], PIONEER AF-PCI [3] rivaroxaban 20/15 mg n = 7840, ARISTOTLE [25] and AUGUSTUS [5] apixaban n = 11,426 and ENGAGE AF-TIMI 48 [26] edoxaban 30 mg n = 7034, edoxaban 60 mg n = 7035 and ENTRUST-AF PCI [6] edoxaban 60 mg n = 751 (total 14,820). This evidence concerns the gene F10 and atrial fibrillation.